DFNB8
TMPRSS3-related progressive hearing loss
Pre-clinicalActive (Licensed to Myrtelle)
Key Facts
Indication
TMPRSS3-related progressive hearing loss
Phase
Pre-clinical
Status
Active (Licensed to Myrtelle)
Company
About Rescue Hearing
Rescue Hearing is a private, preclinical-stage biotech focused on developing curative gene therapies for genetic hearing loss, a condition affecting over 466 million people globally with no approved restorative treatments. The company's pipeline targets specific mutations (DFNB8, DFNB16, USH1B) and leverages a partnership with Myrtelle for its lead DFNB8 program. Led by a CEO with a personal connection to the mission and a CSO who pioneered the first gene therapy for hearing loss to enter human trials, Rescue Hearing aims to address a significant unmet medical need through targeted genetic intervention.
View full company profile